Actinium Pharmaceuticals, Inc.

ATNM Healthcare Biotechnology

Actinium Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $90,000.00, up 11.1% from fiscal 2023.

Revenue
+77,677.8%
EPS
+504.6%
Free cash flow
−4.91%

Quarter to June 2026, against a year earlier

1.42 0.12 +9.23%
Market cap
$40.9M
P/E
3.9×
Fwd P/E
8.4×
Dividend yield
—
F-score
n/a
Altman Z
−11.85
Beneish M
n/a
Dividend safety
n/a

Actinium Pharmaceuticals, Inc. (ATNM) P/E ratio

Alert me on P/E ratio

As of 6 November 2026, Actinium Pharmaceuticals, Inc. (ATNM) trades at a P/E ratio of 3.9×. Over the past ten years it has ranged from 0.0× (June 2026) to 4.4× (October 2026); the current reading is higher than 100% of that period. That is below the Biotechnology industry median of 10.6× and below the Healthcare sector median of 24.5×.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —

Quarterly newest first

Period P/E ratio Change
Jun 2026 2.7× —
Sep 2025 0.0× —
Dec 2022 0.0× —
Sep 2022 0.0× —
6 more quarters

Against its own ten years

Low 0.0× High 4.4×
Ten-year median 0.0×
Current reading's percentile 100

P/E ratio against peers

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on ATNM